Company Overview and News

Cynata Therapeutics Completes Patent Application to Cover Cymerus™ Stem Cell Technology in the Treatment of Side Effects Related to CAR-T Therapy

2018-04-20 globenewswire
MELBOURNE, Australia, April 20, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), today announced that it has completed the filing of a patent application with IP Australia that would cover the therapeutic use of its Cymerus™ stem cell technology in the treatment of adverse reactions associated with chimeric antigen receptor T-cell (CAR-T) immunotherapy.
Upvote Downvote

Cynata Therapeutics granted another patent for its unique stem cell technology

Cynata Therapeutics Ltd (ASX:CYP) has been granted a further patent covering aspects of its proprietary Cymerus™ stem cell platform by the U.S. Patent and Trademark Office (USPTO).
Upvote Downvote

FDA Grants Orphan Drug Designation to Cynata’s Lead Cymerus™ MSC Product, CYP-001

2018-03-28 globenewswire
MELBOURNE, Australia, March 28, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that the United States Food and Drug Administration (FDA) has granted Cynata Orphan Drug Designation for CYP-001 for the treatment of acute graft versus host disease (GvHD). CYP-001 is the lead mesenchymal stem cell (MSC) product manufactured using Cynata’s proprietary Cymerus platform manufacturing technology.
Upvote Downvote

Amzalak closes in on leader Ellis as Jatenergy goes gangbusters

Mendy Amzalak of AMZ Capital has narrowed the gap with race leader Angie Ellis of 80 20 Investments, in week three of the four-week shares race.
Upvote Downvote

Ellis maintains lead as Smart Park fires up

Angie Ellis of 80 20 Investments has maintained her lead over her closest rival, Mendy Amzalak of AMZ Capital, in week two of the four-week shares race with her original $100,000 portfolio worth $114,584.
Upvote Downvote

HC Wainwright repeats 'buy' on Cynata as ongoing trial is cleared by data safety monitoring board

Broker HC Wainwright is bullish on stem cell group Cynata Therapeutics Ltd (ASX:CYP) following encouraging early findings from clinical trials of its CYP-001 treatment for steroid-resistant graft-versus-host disease.
Upvote Downvote

HC Wainright repeats 'buy' on Cynata as ongoing trial is cleared by data safety monitoring board.

Broker HC Wainright is bullish on stem cell group Cynata Therapeutics Ltd (ASX:CYP)following encouraging early findings from clinical trials of its CYP-001 treatment for steroid-resistant graft-versus-host disease.
Upvote Downvote

Cynata Therapeutics wins U.S. patent for stem cell technology

Cynata Therapeutics Ltd (ASX:CYP) has been granted a patent for its proprietary Cymerus™ mesenchymal stem cell technology in the U.S.
Upvote Downvote

Cynata Therapeutics Ltd crosses major milestone in the U.S.

Cynata Therapeutics Ltd (ASX:CYP) has crossed a major milestone by successfully completed the pre-IND (investigational new drug) meeting with the U.S. FDA (Food and Drug Administration).
Upvote Downvote

Glioblastoma Multiforme Pipeline Therapeutics and Drug Profiles Analysis 2017 - RnR Market Research

2017-07-03 prnewswire
Glioblastoma Multiforme Pipeline Therapeutics Development 2017 report provides Companies Involved in Therapeutics Development like AbbVie, Novartis AG, Novogen, Merck KGaA and others. Report encapsulates all the dormant and discontinued Glioblastoma Multiforme pipeline projects.
Upvote Downvote

Cynata Therapeutics achieves progress in stem cell technology

Cynata Therapeutics (ASX:CYP) has received the Notice of Allowance from the U.S. patent office for a patent application tied to its proprietary Cymerus™ stem cell technology.
Upvote Downvote

Regenerative Medicine Market to Grow Over $53.7 Billion by 2021 With 23.3% CAGR Says a Report at

2017-05-17 prnewswire
Global Regenerative Medicine Market Analysis & Forecast to 2021 report provides a comprehensive overview of the size of the regenerative medicine market, segmentation of the market (stem cells, tissue engineering and CAR-T therapy), key players and the vast potential of therapies that are in clinical trials.
Upvote Downvote

Cynata Therapeutics to reveal details on clinical trial

Cynata Therapeutics (ASX:CYP) has some very interesting news on the horizon, with the company entering an ASX trading halt pending an update on its Phase 1 clinical trial. The halt will remain in place until the opening of trade on Wednesday 17th May 2017, or earlier if an announcement will be made to the market.
Upvote Downvote

Global Regenerative Medicine Market Analysis & Forecast 2017-2021 - Research and Markets

2017-05-05 prnewswire
Research and Markets has announced the addition of the "Global Regenerative Medicine Market Analysis & Forecast to 2021 - Stem Cells, Tissue Engineering, BioBanking & CAR-T Industries" report to their offering.
Upvote Downvote

Cynata Therapeutics: Access latest PPT from Proactive's CEO Sessions

Cynata Therapeutics' (ASX:CYP) CEO, Dr Ross Macdonald, joined Proactive's CEO Sessions in Sydney on Tuesday 14th March and Melbourne on Wednesday 15th March.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...